| GENMAB AS DK 1 |
| Dänemark |
| Gesundheit |
| DK0010272202 / 565131 |
| GE9 (Frankfurt) |
| FRA:GE9, ETR:GE9, GE9:GR |
| - |
| https://www.genmab.com/ |
|
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases..
>Volltext.. |
| 15409.9 Mio. EUR |
| 12630.77 Mio. EUR |
| 3197.15 Mio. EUR |
| 1228.99 Mio. EUR |
| 1325.24 Mio. EUR |
| 21.18 EUR |
| 119.55 Mio. EUR |
| 1482.57 Mio. EUR |
| 1142.75 Mio. EUR |
| 4.6 |
| 21.7% |
| 114.91% |
| - |
| - |
| - |
| - |
| GENMAB |
| 18.02.26 |
|